VR Logo

Greenwich LifeSciences Inc. (GLSI) download report


Healthcare | Biotechnology & Pharma Research

Greenwich LifeSciences Inc. (GLSI) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.

IPO Date: 25-Sep-2020

CEO, CFO & Director: Mr. Snehal S. Patel

Founder & Independent Director: Mr. Eric Rothe

Listing: NASDAQ: GLSI

Country: United States

Headquarters: Stafford, TX

Website: https://greenwichlifesciences.com

Key Facts

Market cap: $116.48 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-5.94 Mln

Cash: $19.74 Mln

Total Debt: $0.00 Mln

Insider's Holding: 81.81%

Liquidity: Low

52 Week range: $6.82 - 48.50

Shares outstanding: 13,000,400

Stock Performance

Time Period Greenwich LifeSciences (GLSI) S&P BSE Sensex S&P Small-Cap 600
YTD-64.57-7.86-19.79
1 month-4.33-3.75-9.59
3 months-55.43-10.80-13.28
1 Year-80.001.50-17.92
3 Years--10.755.46
5 Years--11.435.57
10 Years--11.849.48
As on 06-Jul-2022
Year Greenwich LifeSciences (GLSI) S&P Small-Cap 600 S&P BSE Sensex
2021-33.2925.2721.99